AXSM earnings analysis
What we found in AXSM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Axsome delivered strong commercial growth, with Q2 2026 revenue of $218.4 million, up 46% year over year and led by AUVELITY revenue of $180.3 million. EPS of $(0.99) improved from $(1.26) in Q1 but missed consensus of $(0.87) and remained below $(0.97) a year earlier. Cash of $319.9 million supports management’s stated plan to reach cash-flow positivity, but the $115.9 million first-half net loss, ongoing development spending, and debt covenant requirements keep the risk profile elevated.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth accelerated
- Q2 2026 revenue was $218.4 million, up 46% year over year from $150.0 million in Q2 2025 and up 14% sequentially from $191.0 million in Q1 2026.
- AUVELITY remains the growth engine
- AUVELITY generated $180.3 million of Q2 2026 revenue, representing approximately 83% of total quarterly revenue of $218.4 million.
- EPS improved sequentially, not year over year
- Reported EPS was $(0.99), compared with $(1.26) in Q1 2026, an improvement of $0.27 sequentially, but deteriorated from $(0.97) in Q2 2025.
- AXS-12 reached regulatory review
- The FDA accepted the AXS-12 NDA in July 2026 for cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027.
- Liquidity supports ongoing operations
- Cash was $319.9 million at June 30, 2026, compared with $322.9 million at December 31, 2025, and management said it expects current cash to fund operations into cash flow positivity.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses remain substantial
- The company reported a six-month net loss of $115.9 million and an accumulated deficit of $1,421.8 million as of June 30, 2026, indicating continued dependence on commercial growth and liquidity management to reach profitability.
- Debt covenants constrain flexibility
- The Blackstone facility permits aggregate loans of up to $570.0 million and includes a $30.0 million minimum liquidity covenant. A covenant breach could accelerate repayment and terminate further commitments.
- Pharmaceutical tariff exposure increased
- The revised political and trade-risk discussion cites tariffs of up to 100% on certain patented pharmaceuticals and related ingredients, with phased effective dates beginning July 31, 2026 and September 29, 2026. Although management does not currently anticipate a material impact, implementation could pressure pricing and supply-chain economics.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.99
- Segment
- AUVELITY: $180.3 million of Q2 2026 revenue
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management stated that current cash is sufficient to fund anticipated operations into cash flow positivity based on the current operating plan.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 4, 2026
- Axsome Therapeutics reported Q1 2026 revenues of $191.2 million, a notable increase of 57% year-over-year, while EPS was -$1.26, missing estimates by 43%. Management highlighted strong growth from AUVELITY and SUNOSI,…
- 10-K · February 23, 2026
- Axsome’s 2025 10-K shows rapid commercial execution: three launched products (AUVELITY, SUNOSI, SYMBRAVO) generated $638.5 million in 2025 revenue (66% YoY). Gross margins remain high quarter-to-quarter and operating…
- 10-Q · November 3, 2025
- Axsome reported a strong top-line quarter with total revenues of $170,992,000 (product sales $169,784,000) — up $66,230,000 versus Q3 2024 and $20,988,000 versus Q2 2025 — while gross margin remained high at 93.0%.…
- 10-Q · August 4, 2025
- Axsome reported strong Q2 results with total revenues of $150.042M (product sales $148.959M), a 72% increase vs. Q2 2024 ($87.166M), and materially improved operating performance: operating loss narrowed to $(36.714)M…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AXSM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever